The use of albumin in patients with decompensated cirrhosis: The case in favor

Israel Medical Association Journal

Volumn 7, Issue 2, 2005, Pages 115-118

  Maor, Yaakov ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Ascites; Cirrhosis; Decompensation; Hepatorenal syndrome

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; DIURETIC AGENT; MIDODRINE; NORADRENALIN; OCTREOTIDE; ORNIPRESSIN; TERLIPRESSIN; VASOCONSTRICTOR AGENT;

ASCITES; ASCITES FLUID; BACTERIAL PERITONITIS; CIRCULATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DIURESIS; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; HEPATORENAL SYNDROME; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; NOTE; OUTPATIENT CARE; PARACENTESIS; SIDE EFFECT;

ASCITES; DIURETICS; DRUG COSTS; HUMANS; HYPOALBUMINEMIA; LIVER CIRRHOSIS; PERITONITIS; SERUM ALBUMIN;

EID: 13844309576     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (30)

1. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994;20:1359-63.
2. Martin P-Y, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998;339:533-41.
3. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7.
4. Gines P, Rodes J. Clinical disorders of renal function in cirrhosis with ascites, In: Arroyo V, Gines P, Rodes J, Schrier RW, eds. Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment. Malden: Blackwell Science, 1999:36-62.
5. Stein J, Regulation of the renal circulation. Kidney Int 1990;38:571-6.
6. Wong F, Blendis L. New challenge of hepatorenal syndrome: prevention and treatment. Hepatology 2001;34;1242-51.
7. Gines P. Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003;362:1819-27.
8. Arroyo V, Colmenero J. Use of albumin in the management of patients with decompensated cirrhosis. An independent verdict. Dig Liver Dis 2003;35:668-72.
9. Evans TW. Albumin as a drug - biological effects of albumin unrelated to oncotic pressure [Review]. Aliment Pharmacol Ther 2002;16(Suppl 5):6-11.
10. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomized controlled trials. Br Med J 1998;317:235-40.
11. Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998;27:264-72.
12. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the Consensus Conference of the International Ascites Club. Hepatology 2003;38:258-66.
13. Laffi G, Gentilini P, Romanelli RG, La Villa G. Is the use of albumin of value in the treatment of ascites in cirrhosis? The case in favour. Dig Liver Dis 2003;35:660-3.
14. Gentilini P. Casini-Raggi V, Di Fiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999;30:639-45.
15. Vizzutti F, Romanelli RG, Casini-Raggi V, et al. Diuretic and natriuretic effects of long-term albumin infusion in patients with cirrhosis and ascites. J Hepatol 2001;34(Suppl 1):17.
16. Quitero E, Gines P, Arroyo V, et al. Paracentesis versus diuretics in the treatment of cirrhotics with tense ascites. Lancet 1985; 1:611-12.
17. Gines P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988;94:1493-502.
18. Gines A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated with paracentesis. Gastroenterology 1996; 111:1002-10.
19. Sola-Vara J, Minana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003;37:1147-53.
20. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1945-501.
21. Navasa M, Follo A, Filella X, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with development of renal impairment and mortality. Hepatology 1998;27: 1227-32.
22. Sort P, Navasa M, Arroyo V, et al. Effect of plasma volume expansion on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341:403-9.
23. Gines P, Guevara M. Good news for hepatorenal syndrome. Hepatology 2002;36:504-6.
24. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002;36:941-8.
25. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923-30.
26. Uriz J, Gines P, Cárdenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43-8.
27. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 HRS with the administration of midodrine and octreotide. Hepatology 1999;29:1690-7.
28. Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type I hepatorrenal syndrome: a pilot study. Hepatology 2002;36:374-80.
29. Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003;38:238-43.
30. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40:55-64.